Add BrightSurf on Google Email

Wider surgical margins may not mean better cancer control, finds large-scale treatment trial

A new study led by UC Davis researchers finds that narrower surgical margins than previously thought can achieve cancer control in pediatric patients with non-rhabdomyosarcoma soft tissue sarcomas. The study, which evaluated 266 patients, found that close surgical margins as little as a millimeter can preserve precious healthy tissue a...

Major HER2+ breast cancer trial identifies factors associated with pathologic complete response to less intensive chemotherapy

A significant proportion of patients with HER2-positive, ER-negative breast cancer can achieve a pathologic complete response after 12 weeks of THP chemotherapy. The trial identified ER-negative or low ER-expressing tumors, low or no progesterone receptor expression, HER2 IHC 3+ tumors, and weekly paclitaxel treatment as key predictors...

SourceECOG-ACRIN Cancer Research Group·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateOct 6, 2026

ECOG-ACRIN launches a landmark trial to evaluate chemotherapy benefit in high-risk early-stage breast cancer

A new trial will determine whether chemotherapy provides additional benefit for patients with high anatomic risk but low genomic risk. The RxFINE-Low trial will enroll 2,000 postmenopausal women and men with high anatomic risk breast cancer and low genomic risk, and follow them for up to 10 years.

SourceECOG-ACRIN Cancer Research Group·TypeRandomized controlled/clinical trial·DateSep 24, 2026

Pembrolizumab plus chemotherapy for cervical cancer

The study confirms the durability of benefit for pembrolizumab plus chemotherapy as a first-line standard-of-care option for recurrent and metastatic cervical cancer. This treatment regimen has been shown to provide a significant advantage over traditional chemotherapy in patients with this type of cancer.

SourceJAMA Network·JournalJAMA Oncology·DateSep 10, 2026

Mass General Brigham-led trial shows a less-intensive drug combination is more effective in treating AML

A phase 2 clinical trial found that a less-intensive combination of azacitidine and venetoclax was more effective in treating acute myeloid leukemia, with patients tolerating treatment better and spending less time in the hospital. The combination also led to more patients reaching stem cell transplantation.

SourceMass General Brigham·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateSep 2, 2026

Oral therapy protects healthy tissue from radiation in mice

Researchers have developed an oral therapy that protects healthy tissue from radiation while preserving radiation's ability to destroy cancer cells. The therapy, called XOlacta, is packaged in milk-derived extracellular vesicles and can be administered orally, reducing damage to tissues and preserving tumor treatment effectiveness.

SourceVirginia Tech·JournalCancer Letters·TypeExperimental study·DateAug 21, 2026

Risk of herpes zoster among breast cancer survivors in Japan: A nationwide claims data analysis

A nationwide claims data analysis in Japan found breast cancer survivors have a 1.57-fold higher risk of herpes zoster and a 1.70-fold higher risk of postherpetic neuralgia. Vaccination can reduce both the incidence of herpes zoster and the risk of complications, emphasizing the importance of prevention in breast cancer survivorship care.

SourceUniversity of Tsukuba·JournalBreast Cancer Research·DateAug 19, 2026

Preoperative chemo-immunotherapy more effective than immunotherapy alone in patients with head and neck cancer

A study published in JAMA Otolaryngology–Head & Neck Surgery found that preoperative chemo-immunotherapy was more effective than immunotherapy alone in reducing tumor size in patients with head and neck cancer. The study analyzed data from 86 adults with head and neck cancer treated between July 2024 and March 2026, and showed that pat...

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalJAMA Otolaryngology–Head & Neck Surgery·DateAug 13, 2026

Osimertinib with or without chemotherapy in advanced non–small cell lung cancer with EGFR and concurrent TP53 mutations

A randomized phase 3 study found that first-line osimertinib plus chemotherapy significantly improved median progression-free survival compared to osimertinib alone in patients with advanced non–small cell lung cancer (NSCLC) and concurrent EGFR and TP53 mutations. This study provides evidence for incorporating TP53-based molecular ris...

SourceJAMA Network·JournalJAMA·DateAug 10, 2026

Can exercise and ibuprofen lessen cancer-related cognitive impairment?

A Phase II trial found that exercise can improve cognitive function in patients receiving chemotherapy, while low-dose ibuprofen may also have some benefits. The study suggests that exercise is more effective in improving cognitive outcomes, but further research is needed to explore the effects of ibuprofen and combination therapy.

SourceWiley·JournalCancer·DateApr 20, 2026

Landmark Alliance ATOMIC Trial establishes new standard of care for patients with stage III dMMR colon cancer

The phase III Alliance ATOMIC trial shows that adding immunotherapy to standard chemotherapy improves clinical outcomes for patients with stage III dMMR colon cancer. The study found a 50% reduction in cancer recurrence risk and a 86.3% disease-free survival rate at three years.

SourceAlliance for Clinical Trials in Oncology·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateMar 25, 2026

New study finds common blood pressure drug boosts cancer treatment

A new study found that the common blood pressure medication telmisartan can significantly enhance the cancer-killing activity of olaparib, potentially expanding its use to many more patients. Telmisartan made tumors more vulnerable to PARP inhibitors, even when they lacked specific DNA repair defects.

SourceDartmouth Health·JournalJournal for ImmunoTherapy of Cancer·TypeExperimental study·DateMar 25, 2026